-
-
-
-
-
-
-
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territ
-
-
-
-
-
-
-
Check-Cap Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Sol-Gel Technologies Ltd. (SLGL) and Searchlight Pharma Enter Agreements to Commercialize TWYNEO and EPSOLAY in Canada
-
-
-
-
-
-
-
Reunion Neuroscience (REUN) Receives Nasdaq Non-compliance Notice
-
-
-
-
-
-
-
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
-
-
-
-
-
-
-
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
-
-
-
-
-
-
-
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
-
727 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

